Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbapenems in pediatrics.

Kassa Ayalew1, Sumati Nambiar, Yuliya Yasinskaya

  • 1Department of Infectious Diseases, Children's National Medical Center, Washington, DC 20010, USA.

Therapeutic Drug Monitoring
|September 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015-2024.

Therapeutic innovation & regulatory science·2026
Same author

Lessons and Insights from a Case Study on Clinical Trial Fraud.

Therapeutic innovation & regulatory science·2026
Same author

Strategic Demonstration of the Clinical Utility of Nontraditional Antibacterials.

Infectious disease clinics of North America·2025
Same author

Evolving Standards: Good Clinical Practice Insights from US FDA, MHRA UK, and Health Canada.

Clinical pharmacology and therapeutics·2025
Same author

Patient-Reported Outcomes and Health-Related Quality-of-Life Measures in Infectious Diseases Studies and Clinical Practice.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration.

JAMA network open·2025

Carbapenems like imipenem and meropenem are effective antibiotics against resistant bacteria, including those producing extended-spectrum beta-lactamases (ESBLs). They offer broad-spectrum activity and low toxicity for treating serious infections in children.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Rising antimicrobial resistance, particularly from extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria, complicates treatment of severe infections.
  • Third-generation cephalosporins are often ineffective against these resistant pathogens.
  • Carbapenems represent a crucial class of broad-spectrum antibiotics due to their stability against these resistance enzymes.

Purpose of the Study:

  • To review the pharmacokinetic and pharmacodynamic properties of imipenem and meropenem.
  • To discuss the clinical applications of these carbapenems in pediatric populations.
  • To highlight their efficacy in treating various serious bacterial infections.

Main Methods:

  • Literature review of English-language articles from 1980 to present.

Related Experiment Videos

  • Searches conducted using MEDLINE (PubMed) and bibliographies of relevant articles and books.
  • Inclusion of approximately 50% of initially reviewed articles.

    • Main Results:

    • Carbapenems demonstrate efficacy in treating diverse infections such as meningitis, pneumonia, intra-abdominal infections, and bone, joint, and urinary tract infections.
    • Imipenem and meropenem exhibit favorable pharmacokinetic and pharmacodynamic profiles.
    • These antibiotics are generally well-tolerated in pediatric patients.

    Conclusions:

    • Carbapenems are valuable therapeutic options for critically ill children with serious bacterial infections due to their broad spectrum and low toxicity.
    • Judicious use of carbapenems is essential to mitigate the emergence of carbapenem-resistant pathogens.
    • Further research into carbapenem use in pediatric populations is warranted.